
PMI U.S. Hosts Clinic on Legal Support for Veterans
With support from PMI U.S. funding, lawyers and law students from the clinics offer individualized guidance to veterans on navigating complex issues, such as completing Department of Veterans Affairs (VA) benefit applications and accessing resources like mental health services.
Case studies covered:
How insights from an individual case in Florida led to new national policies, practices and legislative proposals.
Expanding outreach to Navajo Nation veterans in Colorado and improving access to benefits through legal and mental health evaluations.
Increasing access and legal assistance for Arizona veterans in rural and Tribal areas.
PMI U.S. contributions in 2024 and 2025 will provide nearly $1 million in funding to veterans' advocacy law clinics to help veterans and their families access the benefits they've earned.
About PMI U.S.
Philip Morris International Inc. is headquartered in Stamford, Connecticut, and its U.S. affiliates (collectively, 'PMI U.S.') employ more than 2,500 people. PMI U.S. is on a mission to improve public health by providing the 45 million nicotine consumers in the U.S. — 30 million of which still smoke traditional cigarettes — with better alternatives. Since 2008, PMI has invested more than $14 billion globally to develop and commercialize FDA-authorized smoke-free products for legal-age nicotine consumers. PMI U.S. operates smoke-free product manufacturing facilities, including Swedish Match North America's Owensboro, Kentucky plant that makes ZYN nicotine pouches and Triaga's facility in Wilson, North Carolina, that produces HEETS as part of the IQOS heated tobacco system. Swedish Match North America has a regional office in Richmond, Virginia.
U.S. marketing practices support 21+ access only
PMI U.S. is committed to responsible marketing practices focused on limiting access to adults 21 years of age and older. PMI U.S. does not use social media influencers in the U.S. or people under the age of 35 — or who appear to be under the age of 35 — in marketing materials. PMI U.S. also employs independent age-verification systems, such as Double Verify, to direct digital advertising to those over 21, and owned digital platforms are age-gated at the point of access and restricted to current nicotine consumers who are 21+. Swedish Match North America is a Manufacturer Advisory Council member of the We Card Program, a national nonprofit serving retailers of age-restricted products. PMI is also a founding board member and investor in TruAge®, a free retail technology that provides stores with a more accurate method of age verification, including the ability to better detect fake IDs, to ensure access is limited to those 21+.
U.S. mission to improve public health through smoke-free products
Because adult nicotine consumer preferences differ, PMI U.S. is working to offer a range of smoke-free options for adults 21+. Since 2008, PMI has invested over $14 billion to develop, scientifically substantiate and commercialize innovative smoke-free products. In 2022, PMI acquired Swedish Match — a leader in oral nicotine delivery — creating a global smoke-free champion led by the ZYN and IQOS brands.
IQOS is authorized by the FDA as a modified risk tobacco product, meaning the FDA has found it appropriate for the promotion of public health. Although IQOS heatsticks are not risk-free and contain nicotine, which is addictive, studies show that because the device heats tobacco instead of burning it, it significantly reduces the production of and exposure to harmful chemicals compared to conventional cigarettes for adults who smoke and who switch to IQOS completely.
In 2025, the FDA authorized all 20 Swedish Match ZYN nicotine pouch products currently sold in the U.S., making ZYN the only FDA-authorized nicotine pouch on the market to help adults who use cigarettes or traditional tobacco products completely switch. The FDA has authorized Swedish Match's General snus as a modified risk tobacco product. Currently, PMI U.S. holds more than 80 percent of modified risk tobacco product authorizations and more than 45 percent of premarket tobacco product authorizations.
Commitment to corporate social responsibility
PMI U.S. has contributed approximately $25 million to charitable causes since 2022, amplifying the good work of organizations already active within communities through both financial contributions and volunteering. PMI U.S.'s philanthropy efforts include supporting military veterans and military spouses, disaster prevention and relief and grassroots economic development. PMI U.S. helped form United to Safeguard America from Illegal Trade, a coalition of nearly 100 national and state brand enforcement experts, law enforcement agencies, academics and leading business organizations working to combat illegal trade. USA-IT has trained more than 36,000 law enforcement officials.
For more information, please visit www.pmi.com/us/ and www.pmiscience.com. 'PMI' refers to the Philip Morris International family of companies. 'PMI U.S.', 'we', 'our', and 'us' refer to PMI's U.S. businesses.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Insider
2 hours ago
- Business Insider
Why Is Replimune Stock (REPL) Down 75% Today?
Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The FDA didn't approve the Biologics License Application (BLA) for RP1 in combination with nivolumab as a treatment for advanced melanoma. Advanced melanoma occurs when the cancer spreads beyond the skin, such as to the lymph nodes, distant organs, or bones. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Replimune CEO Sushil Patel said, 'We are surprised by this FDA decision and disappointed for advanced melanoma patients who have limited treatment options as highlighted by the granting of breakthrough status at the time we provided the IGNYTE primary data.' Replimune intends to request a Type A meeting with the FDA to seek a timely and accelerated approval of RP1. It expects this meeting to be granted within the next 30 days. Replimune Stock Movement Today Replimune stock was down 76.88% in pre-market trading on Tuesday, following a 1.94% rally yesterday. The company's shares have rallied 1.78% year-to-date and 22.76% over the past 12 months. Today's drop came with heavy trading, as some 10 million shares changed hands, compared to a three-month daily average trading volume of 1.63 million shares. Is Replimune Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for Replimune is Strong Buy, based on nine Buy ratings over the past three months. With that comes an average REPL stock price target of $22.43, representing a potential 81.99% upside for the shares.


Business Insider
4 hours ago
- Business Insider
Wainwright Analyst Slaps $0 Price Target on Sarepta Stock (SRPT)
Sarepta Therapeutics (SRPT) is under mounting Wall Street scrutiny amid safety concerns surrounding its flagship gene therapy, Elevidys. In a striking call, analyst Mitchell Kapoor at H.C. Wainwright assigned a $0 price target to SRPT stock, citing the tension between the company and the FDA (Food and Drug Administration). Meanwhile, Kapoor maintained his Sell rating on SRPT stock. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. SRPT stock has plunged more than 30% over the past five trading days, following Friday's news that the FDA requested Sarepta halt all shipments of Elevidys. In response, the company announced a voluntary pause in U.S. shipments of the therapy. For context, Elevidys is a one-time gene therapy from Sarepta that treats Duchenne muscular dystrophy (DMD) in patients aged four and up. HC Wainwright Sees FDA Clash as 'Unwinnable' Kapoor's rare price target cut comes after Sarepta initially refused to voluntarily pause Elevidys shipments, despite an FDA request following three patient deaths linked to the treatment. Additionally, Kapoor called the conflict with the FDA 'unwinnable' and warned that regulators are likely to force Elevidys off the market. A potential withdrawal could wipe out the therapy's revenue stream, leaving Sarepta stock effectively worthless. He also cautioned investors against single-product biotech companies, warning that such a business model may not be sustainable. Other Analysts Weigh In on SRPT Stock After Friday's decline, more than six analysts have downgraded their ratings on Sarepta stock. Notably, both Deutsche Bank Securities and Needham & Co. issued Sell ratings. Needham's analyst Gil Blum believes the ongoing 'showdown' between the FDA and Sarepta will likely end with formal regulatory action against Elevidys. He also warns that a potential market withdrawal could jeopardize Sarepta's ability to meet its $1.15 billion debt obligations due in 2027. On the other hand, J.P. Morgan's analyst Anupam Rama reiterated his Buy rating on SRPT stock, predicting an upside of over 50%. Rama believes Elevidys will likely remain available for ambulatory patients, as no deaths have been reported in that subgroup to date. These patients can walk independently or with minimal support. What is SRPT's Stock Price Forecast? According to TipRanks, Wall Street has a Hold consensus rating on SRPT stock, based on six Buys, 17 Holds, and three Sells assigned in the last three months. The average Sarepta Therapeutics stock price target of $30.82 implies a 131.4% upside potential.
Yahoo
7 hours ago
- Yahoo
A Multi-State Salmonella Outbreak Is Linked to These Frozen Beans — Are They in Your Freezer?
To date, there have been 11 confirmed illnesses across 10 states. The U.S. is experiencing a massive Salmonella outbreak, and the U.S. Food and Drug Administration (FDA) believes it has finally pinpointed the to the FDA, the outbreak was first identified in October 2024, following the first reported case of illness. The most recent individual to fall ill as part of the outbreak was on June 24. The FDA revealed on July 17 that the source of the outbreak is Chetak LLC's Deep-brand frozen sprouted mat (moth) beans and frozen sprouted moong (mung) beans. The agency identified the problem through routine sampling. "The product samples tested positive for Salmonella, and whole genome sequencing analysis determined that the Salmonella present in the samples matched the strain causing illnesses in this outbreak," the FDA added. It noted that, to date, 11 people have been reported ill in connection with the outbreak from 10 different states, including Connecticut, Florida, Illinois, Massachusetts, Minnesota, New Jersey, Pennsylvania, Tennessee, Virginia, and Washington. In response to the news, the brand and the FDA issued a recall notice for several of its products. The recall includes the following:Deep-brand Sprouted Mat (Moth) in one-pound (454 grams) packages with the following lot codes printed on the back side of the bag: IN 24330, IN 25072, IN 25108, IN 24353, IN 25171, IN 24297, IN 25058, IN 25078, IN 24291, IN 25107, IN 24354, IN 24292 Related: America Has a Growing Food Safety Crisis No One Is Talking About Deep-brand Sprouted Moong (Mung) in one-pound (454 grams) packages with the following lot codes printed on the back side of the bag: IN 24330, IN 25072, IN 25108, IN 24353, IN 25171, IN 24297, IN 25058, IN 25078, IN 24291, IN 25107, IN 24354, IN 24292 Salmonella, the FDA explained, is a "group of bacteria that can cause gastrointestinal illness and fever called salmonellosis." It added that it can spread through food handlers who "do not wash their hands and/or the surfaces and tools they use between food preparation steps, and when people eat raw or undercooked foods." While most people infected with Salmonella recover without treatment, those with weakened immune systems, children, or the elderly are especially vulnerable to severe cases. Usually, symptoms appear within 12 to 72 hours after infection and can include diarrhea, fever, and abdominal cramps, according to the FDA. Though more severe cases of salmonellosis may involve a "high fever, aches, headaches, lethargy, a rash, blood in the urine or stool, and in some cases may become fatal." According to the U.S. Centers for Disease Control and Prevention, "approximately 450 persons in the United States die each year from acute salmonellosis." If you've purchased the product, the FDA recommends that you discard it immediately. If you've already consumed the product and become ill, contact your healthcare provider right away. Read the original article on Food & Wine Solve the daily Crossword